[Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole].
BACKGROUND
Prospective studies of Graves-Basedow disease in Spain are scarce. Our objective was to evaluate the clinical and biochemical evolution of a cohort of patients with Graves-Basedow disease.


METHODS
202 patients with Graves-Basedow disease diagnosed between January 1997 and June 1999.


RESULTS
5.9% of patients received 131I and 2.5% underwent surgery after treatment with methimazole. A relapse was observed in 23.3% patients. In the survival analysis, significant differences with regard to the rate of relapse were observed according to the goitre degree.


CONCLUSIONS
In our study, all patients reached remission with methimazole. There was a high rate of relapse following discontinuation of therapy within the first months. Goitre size at the time of diagnosis was a significant determining factor of relapse.
De Luis
Daniel Antonio
DA
Sección de Endocrinología y Nutrición Clínica, Hospital del Río Hortega, Valladolid, Instituto de Endocrinología y Nutrición Clínica, Facultad de Medicina de Valladolid, Spain.
Arconada
Ana
A
Aller
Rocío
R
Cuéllar
Luis Angel
LA
Terroba
María Concepción
MC
Martín Gil
Javier
J
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D013956:Antithyroid Agents / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D005260:Female; D006111:Graves Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D008713:Methimazole
Evolución clínica de una cohorte de pacientes con enfermedad de Graves-Basedow tratados con metimazol.